Clinical Trials List
2012-05-15 - 2020-09-08
Phase III
Terminated4
ICD-10C45.9
Mesothelioma, unspecified
ICD-10C79.9
Secondary malignant neoplasm of unspecified site
ICD-10C7A.00
Malignant carcinoid tumor of unspecified site
ICD-10C7A.094
Malignant carcinoid tumor of the foregut NOS
ICD-10C7A.095
Malignant carcinoid tumor of the midgut NOS
ICD-10C7A.096
Malignant carcinoid tumor of the hindgut NOS
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.00
Secondary carcinoid tumors, unspecified site
ICD-10C80.1
Malignant (primary) neoplasm, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.1
Malignant neoplasm of unspecified site (primary) (secondary)
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chiun Hsu 無
- TA-CHEN HUANG 無
- James Chih-Hsin Yang 無
- Chih-Hung Hsu 無
- 張端瑩 無
- Chong-Jen Yu 無
- SHIH-HUNG YANG 無
- Ann-Lii Cheng 無
- 林育麟 無
- SUNG-HSIN KUO 無
- 王秀伯 無
- Chia-Chi Lin 無
- SHIH-HUNG YANG 未分科
- Jih-Hsiang Lee 無
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wen-Chi Chou Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
302 participants
